EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Histone Deacetylase 6 Brain PET in Amyotrophic Lateral Sclerosis‐Frontotemporal Spectrum Disorder

Greet Vanderlinden iD, Charles Carron, Donatienne Van Weehaeghe, Joke De Vocht, Fouke Ombelet, Pegah Masrori, Caro De Weerdt, Rebecca E James, Lauren T Evans, Frederick A Schroeder, Jacob M Hooker, Michel Koole und 4 weitere

Annals of Clinical and Translational Neurology · 2025

DOI: 10.1002/acn3.70067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2025. Verfasst von Greet Vanderlinden und 15 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Positron-Emission Tomography, Histone Deacetylase 6, Frontotemporal Dementia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Association for Frontotemporal Degeneration, Target ALS, Eikonizo Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective [ 18 F]EKZ‐001 is a positron emission tomography (PET) tracer targeting histone deacetylase 6 (HDAC6), an enzyme responsible for intracellular transport and clearance of misfolded proteins. HDAC6 modulation is a promising treatment strategy in neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). Apart from motor symptoms, people with ALS (pwALS) can show a variable degree of cognitive impairment as part of the ALS‐frontotemporal spectrum disorder (ALS‐FTSD). This work assessed [ 18 F]EKZ‐001 binding in pwALS with variable involvement of FTSD. Methods Twenty‐four pwALS (13M/11F, 61 ± 10 years) and 12 healthy controls (HC) (6M/6F, 58 ± 3 years) were included. Thirteen pwALS were cognitively normal (ALS‐CN), and eleven pwALS presented with FTSD (ALS‐FTSD) ranging from mild cognitive or behavioral impairment to FTD, according to their performance on the Edinburgh cognitive and behavioral ALS screen (ECAS). All subjects underwent dynamic PET‐MR imaging with arterial sampling, and regional distribution volumes ( V T ) were calculated using a Logan graphical analysis. Results [ 18 F]EKZ‐001 V T was significantly lower in pwALS compared to HC. For ALS‐CN, the largest reduction was found in the brainstem. For ALS‐FTSD, reductions were more widespread in both gray and white matter. No differences in V T were found between pwALS with and without a C9orf72 mutation. [ 18 F]EKZ‐001 V T was not correlated with ECAS scores, age, or disease duration. Interpretation [ 18 F]EKZ‐001 binding is lower throughout the brain in pwALS compared to HC. This may be related to a compensatory mechanism to repair intracellular transport defects in ALS or to reduced HDAC6 enzyme availability for [ 18 F]EKZ‐001 binding due to sequestration of HDAC6 within protein aggregates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisPositron-Emission TomographyHistone Deacetylase 6Frontotemporal DementiaBrainCognitive DysfunctionHumansMiddle AgedFemaleMaleAged

Stichwörter der Autor:innen

amyotrophic lateral sclerosishistone deacetylase 6positron emission tomography

Substanzen

Histone Deacetylase 6HDAC6 protein, human

Autor:innen und Institutionen

  • Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
  • Division of Nuclear Medicine, University Hospitals UZ Leuven, Leuven, Belgium.
  • Nuclear Medicine, Ghent University Hospital, Ghent, Belgium.
  • Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Neurosciences, Experimental Neurology, KU Leuven, Leuven Brain Institute, Leuven, Belgium.
  • Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neuroscience, UCLouvain, Brussels, Belgium.

ORCID-Profile: Greet Vanderlinden, Philip Van Damme

Förderung

  • Association for Frontotemporal Degeneration
  • Target ALS
  • Eikonizo Therapeutics

Zitieren

APA

Vanderlinden, G., Carron, C., Van Weehaeghe, D., De Vocht, J., Ombelet, F., Masrori, P., De Weerdt, C., James, R. E., Evans, L. T., Schroeder, F. A., Hooker, J. M., Koole, M., Kranz, J. E., Gilbert, T. M., Van Damme, P., & Van Laere, K. (2025). Histone Deacetylase 6 Brain PET in Amyotrophic Lateral Sclerosis‐Frontotemporal Spectrum Disorder. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.70067

Vancouver

Vanderlinden G, Carron C, Van Weehaeghe D, De Vocht J, Ombelet F, Masrori P, et al. Histone Deacetylase 6 Brain PET in Amyotrophic Lateral Sclerosis‐Frontotemporal Spectrum Disorder. Annals of Clinical and Translational Neurology. 2025. doi:10.1002/acn3.70067

BibTeX
@article{Vanderlinden2025,
  author = {Vanderlinden, Greet and Carron, Charles and Van Weehaeghe, Donatienne and De Vocht, Joke and Ombelet, Fouke and Masrori, Pegah and De Weerdt, Caro and James, Rebecca E and Evans, Lauren T and Schroeder, Frederick A and Hooker, Jacob M and Koole, Michel and Kranz, Janice E and Gilbert, Tonya M and Van Damme, Philip and Van Laere, Koen},
  title = {Histone Deacetylase 6 Brain PET in Amyotrophic Lateral Sclerosis‐Frontotemporal Spectrum Disorder},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  doi = {10.1002/acn3.70067}
}
Kostenlos starten →